EC Pharmacology and Toxicology

Research Article Volume 13 Issue 11 - 2025

Systematic Review on Liposomes and Nanoparticles: New Delivery Vectors for Targeted and Optimized Therapy

Nafi I1*, Lefhal M3, Bhirich N1 and Rahali Y1,2

1Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

2Ibn Sina University Hospital Center, Rabat, Morocco

3Faculty of Medicine and Pharmacy, Casablanca, Morocco

*Corresponding Author: Nafi I, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Received: June 23, 2025; Published: October 21, 2025



The use of liposomes and other nanoparticles in therapeutics relies on a fundamental advance in pharmacotechnology. These nanoscale systems offer new opportunities in targeting, biodistribution, and side effect mitigation, particularly in the treatment of cancer and chronic diseases. This review discusses the physicochemical properties of nanoparticles and liposomes, their modes of action, existing nanocarriers, and the challenges related to their clinical evaluation and industrialization. Recent results indicate a growing interest in these systems, but limitations remain related to their stability, cost, and regulation.

 Keywords: Liposomes; Nanoparticles; Nanomedicines; Targeting; Vectorization; Pharmacotechnology

  1. Couvreur P. “Les nanotechnologies pour la conception de nouveaux medicaments”. Biologie4 (2020): 237-248.
  2. Hermal F. “Recouvrement et modification de nanoparticules afin d’optimiser leurs propriétés physico-chimiques pour des applications pharmaceutiques” (2020).
  3. Horcajada P., et al. “Des nanovecteurs hybrides pour la restitution retard de médicaments antitumoraux et antiviraux”. Medical Sciences (Paris)8-9 (2020): 761-767.
  4. Lorin A., et al. “Les liposomes: description, fabrication et applications”. Biotechnology, Agronomy, Society and Environment3 (2004): 163-176.
  5. Maja L., et al. “Sustainable technologies for liposome preparation”. The Journal of Supercritical Fluids 165 (2020): 104984.
  6. Ong SGM., et al. “Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes”. Pharmaceutics3 (2016): 25.
  7. Kelly C., et al. “Targeted liposomal drug delivery to monocytes and macrophages”. Journal of Drug Delivery (2011): 727241.
  8. van Furth R., et al. “Le système phagocytaire mononucléaire: nouvelle classification des macrophages, des monocytes et de leurs cellules souches”. Bulletin de l’Organisation Mondiale de la Santé5 (2019): 651-658.
  9. Hayashi H., et al. “Temperature-dependent associating property of liposomes modified with a thermosensitive polymer”. Bioconjugate Chemistry3 (2018): 382-389.
  10. Lee KD., et al. “Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes”. Biochemistry3 (2020): 889-899.
  11. “Liposome”. In: Wikipedia (2025).
  12. Canada E and D social. “Nanoparticules fabriquées: Aspects liés à la santé et à la sécurité” (2021).
  13. Henriques PS. “Les nanoparticules: petites par la taille, grandes par l’impact” (2021).
  14. Qu’est-ce que les nanoparticules et quels en sont les risques?. Novethic (2023).
  15. Sphéroplexes: nanoparticules hybrides lipide/polymère | UTCBS - Unité de Technologies Chimiques et Biologiques pour la Santé (2023).
  16. Nanocomposite de polymère. In: Wikipédia (2023).
  17. Bose A., et al. “Nanomicelles: Types, properties and applications in drug delivery”. IET Nanobiotechnology 1 (2021): 19-27.
  18. Nanomicelles - an overview | ScienceDirect Topics (2022).
  19. Academy CI. “Nanomicelles: A perfect drug delivery carrier for cancer treatment”. UPSC Current Affairs (2020).
  20. Koo OM., et al. “Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine”. Nanomedicine1 (2005): 77-84.
  21. Nikken Wiradharma., et al. “Self-assembled polymer nanostructures for delivery of anticancer therapeutics”. Nano Today4 (2009): 302-317.
  22. Adams ML., et al. “Amphiphilic block copolymers for drug delivery”. Journal of Pharmaceutical Sciences 7 (2003): 1343-1355.
  23. Nanomicelles Delivery Systems (2021).
  24. Lavasanifar A., et al. “Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery”. Advanced Drug Delivery Reviews 54 (2021): 169-190.
  25. PR Velagaleti., et al. “Administration topique de médicaments hydrophobes à l’aide d’une nouvelle technologie nanomicellaire mixte pour traiter les maladies des segments antérieur et postérieur de l’œil”. Drug Delivery Technology 4 (2010): 42-47.
  26. Kabanov AV., et al. “Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery”. Journal of Controlled Release 2-3 (2002): 189-212.
  27. Yoncheva K., et al. “Stabilized micelles as delivery vehicles for paclitaxel”. International Journal of Pharmaceutics 1-2 (2012): 258-264.
  28. Lee ES., et al. “Polymeric micelle for tumor pH and folate-mediated targeting”. Journal of Controlled Release 1-2 (2003): 103-113.
  29. Crater JS and Carrier RL. “Barrier properties of gastrointestinal mucus to nanoparticle transport”. Macromolecular Bioscience 12 (2010): 1473-1483.
  30. In: Wikipédia (2023).
  31. Rivière P. “Les dendrimères: un remède aux maladies inflammatoires chroniques?”. Salle de presse de l’Inserm (2021).
  32. Masson E. “Les nanoparticules”. EM-Consulte (2025).
  33. Collet C., et al. “Lutter contre le cancer avec le ciblage moléculaire”. The Conversation (2022).
  34. Laguerre K. “Ciblage actif de cancers résistants par des nanoparticules multifonctionnelles: synthèse et évaluation biologique”. [These en préparation]. Université Paris-Saclay (2023).
  35. StudySmarter FR. “Libération Contrôlée: Médicaments & Types”. StudySmarter (2023).
  36. “Doxil (liposomal doxorubicin): What to Expect, Side Effects, and More” (2022).
  37. “Haute Autorité de Santé - MYOCET (doxorubicine (chlorhydrate de))” (2022).
  38. Haute Autorité de Santé. DAUNOXOME (daunorubicine (chlorhydrate de)) (2022).
  39. Nanomédicaments contre le cancer | CultureSciences-Chimie (2022).
  40. Résumé des caractéristiques du produit - AMBISOME liposomal 50 mg, poudre pour dispersion pour perfusion - Base de données publique des médicaments (2022).
  41. Amphotericine B LIPOsomale - AMBISOME(md): AMBISOME(md) (2023).
  42. Maladies auto-immunes: des nanoparticules stoppent leur évolution (2023).
  43. Nanosphère: aperçu | ScienceDirect (2023).
  44. INNOVATION | Des nanotechnologies pour diversifier les traitements (2023).
  45. Se servir de l’IA pour traiter le cancer | Actualités | CORDIS | Commission européenne (2023).
  46. Loison A. Comportement client avec l’utilisation des nanoparticules (2021).
  47. Nanotechnologies et IA: innover en biologie cellulaire et en santé.
  48. van der Braak K., et al. “The score after 10 years of registration of systematic review protocols”. Systematic Reviews 11 (2022): 191.
  49. Koensgen N., et al. “Inconsistencies in study eligibility criteria are common between non-Cochrane systematic reviews and their protocols registered in PROSPERO”. Journal of Clinical Epidemiology 137 (2021): 34-41.
  50. Page MJ., et al. “Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality”. Journal of Clinical Epidemiology 100 (2018): 103-110.

Nafi I., et al. “Systematic Review on Liposomes and Nanoparticles: New Delivery Vectors for Targeted and Optimized Therapy”. EC Pharmacology and Toxicology  13.11 (2025): 01-14.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net